Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q1 2024 · 10-Q
Revenue$156.24M$156.24M+13.9% vs Q1 2023 Net Income-$27.06M-$27.06MN/M vs Q1 2023 EPS Diluted-$0.21-$0.21N/M vs Q1 2023 Gross Profit$65,469,000+19.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flow-$25,915,000N/M Free Cash Flowderived-$31,500,000N/M Margins · derivedGross margin41.9%+2.0 pt vs Q1 2023
Operating margin-19.6%+6.0 pt vs Q1 2023
Net margin-17.3%+5.1 pt vs Q1 2023
ended Mar 31, 2024 · filed Apr 30, 2024 · 30 d after period end